ReviewFrontiers in veterinary science2025
Arginine vasopressin and copeptin: comparative review and perspective in veterinary medicine.
Review in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The hypothalamic-neurohypophyseal system in preeclampsia: a systematic review with a subgroup meta-analysis of copeptin levels worldwide.Frontiers in endocrinology · 2026Pooled it
- Dual Aetiology of Diabetes Insipidus in Pregnancy: Vasopressinase-Mediated and Central Mechanisms.Case reports in nephrology · 2026Article
- Plasma Arginine Vasopressin and Serum Copeptin Concentrations at Rest and After Osmotic- and Non-Osmotic-Based Stimulation Tests in Dogs.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although arginine vasopressin (AVP) deficiency, AVP resistance, and primary polydipsia are important causes of polyuria and polydipsia (PUPD), measurement of AVP has never been implemented as a routine diagnostic test for patient care in either human or veterinary medicine, due to significant challenges with the methodologic reliability of laboratory assays for measuring AVP. Responses to a modified water deprivation test and/or a desmopressin acetate trial have been used as indirect markers of AVP deficiency or resistance. However, interpretations of these tests can be especially challenging in cases of partial AVP deficiency or resistance. Over the past decade, plasma copeptin (CoP), a glycopeptide comprising the C-terminal part of the AVP preprohormone, has mostly replaced AVP measurement in humans. When combined with CoP-based stimulation tests, such as hypertonic saline and arginine stimulation tests, plasma CoP measurement offers excellent diagnostic accuracy for the diagnosis and differentiation of cases of central diabetes insipidus (DI), nephrogenic DI, and primary polydipsia in humans. In dogs, CoP has recently been measured in saliva and serum using canine or human enzyme-linked immunosorbent assays. This review will provide an update on the physiologic regulation of AVP production and secretion, the limitations of its measurement in human and veterinary medicine, as well as a summary of the indications and performance of CoP measurement in human and veterinary medicine to date. This is with a purpose to encourage validation and implementation of CoP measurement in veterinary medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.